Cargando…

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab

Membranous nephropathy (MN) with anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN) is seen infrequently. Previous reports of patients with ANCA-GN with MN showed that the most frequent ANCA subtype was myeloperoxidase-ANCA. We herein present a 73-year-old woman with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Shun, Hanai, Shunichiro, Nakagomi, Daiki, Kobayashi, Kei, Takahashi, Kazuya, Furuya, Fumihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835465/ https://www.ncbi.nlm.nih.gov/pubmed/32830174 http://dx.doi.org/10.2169/internalmedicine.4752-20

Ejemplares similares

An unusual adverse event of azathioprine: Cutaneous small vessel vasculitis
por: Hanai, Shunichiro, et al.
Publicado: (2021)

Diffuse large B-cell lymphoma mimicking granulomatosis with polyangiitis and otitis media with antineutrophil cytoplasmic antibodies-associated vasculitis
por: Kobayashi, Yoshiaki, et al.
Publicado: (2022)

Intra-temporalis Muscular Abscess Mimicking Giant Cell Arteritis
por: Kobayashi, Kei, et al.
Publicado: (2021)

Internal Hemorrhaging of Hepatic Hemangioma Presenting with a Fever
por: Hanai, Shunichiro, et al.
Publicado: (2021)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Glomeruloid Hemangioma in a Patient with TAFRO Syndrome
por: Osano, Keiichi, et al.
Publicado: (2022)

Circulating autoreactive proteinase 3(+) B cells and tolerance checkpoints in ANCA-associated vasculitis
por: Berti, Alvise, et al.
Publicado: (2021)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR/ACR provisional classification criteria for polymyalgia rheumatica
por: Kobayashi, Kei, et al.
Publicado: (2021)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Membrane expression of neutrophil proteinase 3 (PR3) is associated with relapse in PR3-ANCA related vasculitis
por: Rarok, AA, et al.
Publicado: (2002)

Reactivity against Complementary Proteinase-3 Is Not Increased in Patients with PR3-ANCA-Associated Vasculitis
por: Tadema, Henko, et al.
Publicado: (2011)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis
por: Thompson, Gwen E., et al.
Publicado: (2020)

Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment
por: Nasrallah, Mazen, et al.
Publicado: (2015)

Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab
por: Khan, Afsha, et al.
Publicado: (2010)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Exploring Frequencies of Circulating Specific Th17 Cells against Myeloperoxidase and Proteinase 3 in ANCA Associated Vasculitis
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

Molecular mimicry among human proteinase 3 and bacterial antigens: implications for development of c-ANCA associated vasculitis
por: Chavez, Y, et al.
Publicado: (2022)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Differences between myeloperoxidase-antineutrophil cytoplasmic autoantibody (ANCA) and proteinase 3-ANCA associated vasculitis: A retrospective study from a single center in China
por: Wu, Ting, et al.
Publicado: (2021)

Correction to: Molecular mimicry among human proteinase 3 and bacterial antigens: implications for development of c-ANCA associated vasculitis
Publicado: (2022)

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism
por: Casal Moura, Marta, et al.
Publicado: (2023)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study
por: Mimura, Norihiro, et al.
Publicado: (2023)

Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial
por: Furuta, Shunsuke, et al.
Publicado: (2017)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vf36cstgq58ksu5jpm9rnmntoh